# Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial

Source: https://onco.cc/trials/nct07722754/  
OnCo record `nct07722754` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of cetuximab, fOLFIRI (5-FU, leucovorin, irinotecan), bevacizumab (glioblastoma use) and sintilimab in colorectal cancer, run by Guangdong Provincial People's Hospital, now recruiting.

## Summary

Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial is a phase 2, randomised interventional study registered as NCT07722754 by Guangdong Provincial People's Hospital, with a registry enrolment figure of 160 participants, started 2026-07-23 and due to reach its primary completion in 2028-07-31. Interventions recorded: Cetuximab; Irinotecan; Bevacizumab; Sintilimab. Conditions listed: Colorectal Neoplasms Malignant; Neoplasm, Metastatic. Primary outcome: Objective Response Rate. Colorectal eligibility wording from the registry: "* Metastatic and unresectable colorectal adenocarcinom;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: BOND-4
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07722754
- Phase: 2
- Setting: A Randomized, Multi-center, Open-label Phase II Trial of Irinotecan and Cetuximab With or Without the Combination of Bevacizumab and Sintilimab in RAS Wild-type, Irinotecan-refractory Metastatic Colorectal Cancer
- Sponsor: Guangdong Provincial People's Hospital
- Enrolled: 160

## Sources

- ClinicalTrials.gov NCT07722754: https://clinicaltrials.gov/study/NCT07722754

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [Sintilimab](https://onco.cc/drugs/sintilimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07722754.json